A Prospective Study of Spasticity in Individuals With Multiple Sclerosis

Status unconfirmed

Conditions studied: Spasticity

In brief

This study is expected to contribute to the body of knowledge on the benefits of individuals with MS taking glatiramer acetate (Copaxone®). If patients have less spasticity when taking glatiramer acetate (Copaxone®), they may be more likely to have an improved quality of life. The hypotheses for this study are: 1. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a decrease in spasticity. 2. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a change in perceptions of the impact of spasticity on their lives.

Key facts

Study ID

NCT01111435

Run by

Fraser, Cira, Ph.D., RN, ACNS-BC

People needed

110

Starts

2010-04-01

Expected to finish

2012-12-01

Last updated by the study team

2012-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Stopped interferon (beta-1a or beta-1b) within the past 30 days
• About to start or started glatiramer acetate (Copaxone®) within the past 21 days.
• At least 18 years of age
• Has spasticity at the beginning of the study
• Able to ambulate with unilateral support or without support
• Understands, speaks and reads English

You may not qualify if…

• Severe Gait Disability or Total Gait Disability

Where it is running

• Shared Solutions Call Center — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.